KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $200.8 million.

  • Biomarin Pharmaceutical's Retained Earnings rose 16281.45% to $200.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $200.8 million, marking a year-over-year increase of 16281.45%. This contributed to the annual value of -$194.7 million for FY2024, which is 6867.61% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Retained Earnings of $200.8 million as of Q3 2025, which was up 16281.45% from $231.5 million recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Retained Earnings peaked at $231.5 million during Q2 2025, and registered a low of -$930.8 million during Q4 2021.
  • Moreover, its 5-year median value for Retained Earnings was -$682.3 million (2023), whereas its average is -$544.2 million.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Retained Earnings plummeted by 802.58% in 2021 and then skyrocketed by 16281.45% in 2025.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Retained Earnings stood at -$930.8 million in 2021, then grew by 15.21% to -$789.2 million in 2022, then grew by 21.24% to -$621.6 million in 2023, then surged by 68.68% to -$194.7 million in 2024, then skyrocketed by 203.12% to $200.8 million in 2025.
  • Its last three reported values are $200.8 million in Q3 2025, $231.5 million for Q2 2025, and $19.2 million during Q1 2025.